After preconditioning with chemotherapy, F01 will be evaluated.
Sponsors
Shanghai Simnova Biotechnology Co.,Ltd.
Conditions
Lupus ErythematosisNon-Hodgkin's Lymphoma
Phase 1
F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma
NCT06206902
Start: 2024-04-30End: 2025-12-31Target: 55Updated: 2024-02-23
F01 in the Treatment of Moderate-to-severe Refractory Systemic Lupus Erythematosus
Not yet recruitingNCT06468683
Start: 2024-06-15End: 2027-12-31Target: 50Updated: 2024-06-21